Chest pain doesn't necessarily come from the heart. An estimated 200,000 Americans each year experience non-cardiac chest pain, which in addition to pain can involve painful swallowing, discomfort and anxiety.
Non-cardiac chest pain can be frightening for patients and result in visits to the emergency room because the painful symptoms, while often originating in the esophagus, can mimic a heart attack. Current treatment — which includes pain modulators such as selective serotonin reuptake inhibitors (SSRI) — has a partial 40 to 50 percent response rate in alleviating symptoms.
New research authored by Temple University Hospital gastroenterologist Ron Schey, MD, FACG, suggests a novel approach to treating non-cardiac chest pain due to esophageal hypersensitivity. The treatment involves a drug called dronabinol, a cannabinoid receptor activator that has traditionally been used to treat nausea and vomiting in HIV patients and for cancer patients undergoing chemotherapy,
In a pilot study involving 13 patients with non-cardiac chest pain, Dr. Schey and his research team found that patients who were given 5 mg of dronabinol twice daily for four weeks fared better than patients who took a placebo, or dummy pill. Those getting dronabinol experienced improved pain tolerance and decreased frequency and intensity of chest pain. In addition, no significant adverse effects were reported.
"This novel study has promising findings in future treatment for these patients," said Dr. Schey, Associate Professor of Medicine at Temple University School of Medicine, who conducted the research while on staff at the University of Iowa Hospitals and Clinic, and analyzed the data at Temple along with Zubair Malik, MD, a first-year fellow in Temple's Division of Gastroenterology.
The pilot study, while encouraging, was very small and not designed to test dronabinol against current therapies for non-cardiac chest pain, so it is difficult to calculate how the drug performs in comparison to existing treatments, Dr. Schey said. He said dronabinol likely helps to diminish pain by activating cannabinoid receptors in the esophagus that decrease sensitivity.
The abstract was presented October 20 in Philadelphia at the Annual Scientific Meeting of the American College of Gastroenterology. The professional organization said it picked the Temple research to be among the "most newsworthy" studies presented at the conference because the findings have an impact on GI patient care.
Dr. Schey joined Temple in 2014; and his research interests include non-cardiac chest pain, GI motility disorders and esophageal disorders.
Dr. Schey said a larger scale study on the effects of dronabinol on non-cardiac chest pain will be initiated in the near future at Temple.
Editor's Note: Neither Dr. Schey nor any member of his immediate family has financial interest in AbbVie, the manufacturer of Marinol®, the brand name of dronabinol.
About Temple Health
Temple University Health System (TUHS) is a $1.4 billion academic health system dedicated to providing access to quality patient care and supporting excellence in medical education and research. The Health System consists of Temple University Hospital (TUH), ranked among the "Best Hospitals" in the region by U.S. News & World Report; TUH-Episcopal Campus; TUH-Northeastern Campus; Fox Chase Cancer Center, an NCI-designated comprehensive cancer center; Jeanes Hospital, a community-based hospital offering medical, surgical and emergency services; Temple Transport Team, a ground and air-ambulance company; and Temple Physicians, Inc., a network of community-based specialty and primary-care physician practices. TUHS is affiliated with Temple University School of Medicine.
Temple University School of Medicine (TUSM), established in 1901, is one of the nation's leading medical schools. Each year, the School of Medicine educates approximately 840 medical students and 140 graduate students. Based on its level of funding from the National Institutes of Health, Temple University School of Medicine is the second-highest ranked medical school in Philadelphia and the third-highest in the Commonwealth of Pennsylvania. According to U.S. News & World Report, TUSM is among the top 10 most applied-to medical schools in the nation.
Temple Health refers to the health, education and research activities carried out by the affiliates of Temple University Health System (TUHS) and by Temple University School of Medicine. TUHS neither provides nor controls the provision of health care. All health care is provided by its member organizations or independent health care providers affiliated with TUHS member organizations. Each TUHS member organization is owned and operated pursuant to its governing documents.
Jeremy Walter | Eurek Alert!
Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University
The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
02.12.2016 | Medical Engineering
02.12.2016 | Agricultural and Forestry Science
02.12.2016 | Physics and Astronomy